Clinical characteristics, treatment outcomes, and relapse prediction in 199 patients with generalized pustular psoriasis: a retrospective cohort study
Biologics, particularly IL-36 inhibitors, improve GPP outcomes. DBIL is a novel biomarker for relapse risk. The validated online tool provides a practical way to personalize relapse prevention and treatment in clinical practice.
Authors
- Z. Zhang
- Hong‐Han Ge (ORCID: https://orcid.org/0009-0004-0368-4599)
- Hong Liu (ORCID: https://orcid.org/0000-0001-5315-3295)
- Xiaoxiao Wu (ORCID: https://orcid.org/0000-0002-1515-9546)
- Zhen Li (ORCID: https://orcid.org/0000-0003-1177-2818)
- Yan Liu (ORCID: https://orcid.org/0000-0002-2566-6867)
- Zhenzhen Wang (ORCID: https://orcid.org/0000-0001-5927-2471)
- Guoyan Liu (ORCID: https://orcid.org/0000-0003-4429-6336)
- Baoqi Yang (ORCID: https://orcid.org/0000-0003-3521-7130)
- Qing Yang (ORCID: https://orcid.org/0000-0002-9730-0901)
- Furen Zhang
- Li Zhu (ORCID: https://orcid.org/0009-0003-7557-2417)
Institutions
- Academy of Medical Sciences (GB)
- Shandong University of Traditional Chinese Medicine (CN)
- Shandong Provincial Institute of Dermatology and Venereology (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1080/09546634.2025.2578253
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00